Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Aficamten in Healthy Adults
NCT03767855Phase 1Completed
- Sponsor
- Cytokinetics
- Start
- Dec 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aficamten in hypertrophic cardiomyopathy (HCM) (8 arms), sponsored by Cytokinetics. Primary endpoint: Incidence of Adverse events and Safety Signals. Started Dec 2018; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT03767855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767855.